Interfering with Metabolic Profile of Triple‐Negative Breast Cancers Using Rationally Designed Metformin Prodrugs. (6th May 2021)

• Record Type: Journal Article
• Authors: Babak, Maria V.; Chong, Kai Ren; Rapta, Peter; Zannikou, Markella; Tang, Hui Min; Reichert, Lisa; Chang, Meng Rui; Kushnarev, Vladimir; Heffeter, Petra; Meier‐Menches, Samuel M.; Lim, Zhi Chiaw; Yap, Jian Yu; Casini, Angela; Balyasnikova, Irina V.; Ang, Wee Han
• Is Part Of: Angewandte Chemie. Volume 133:Number 24(2021)
• Page Start: 13517
• Page End: 13525
• Publication Date: 2021-05-06
• Subjects: antitumor agents -- drug discovery -- metabolism -- metformin -- prodrugs; Chemistry -- Periodicals; 540
• DOI: 10.1002/ange.202102266
• Languages: English
• ISSNs: 0044-8249

Abstract

Abstract: Triple‐negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by an aberrant metabolic phenotype with high metastatic capacity, resulting in poor patient prognoses and low survival rates. We designed a series of novel Au III cyclometalated prodrugs of energy‐disrupting Type II antidiabetic drugs namely, metformin and phenformin. Prodrug activation and release of the metformin ligand was achieved by tuning the cyclometalated Au III fragment. The lead complex 3met was 6000‐fold more cytotoxic compared to uncoordinated metformin and significantly reduced tumor burden in mice with aggressive breast cancers with lymphocytic infiltration into tumor tissues. These effects was ascribed to 3met interfering with energy production in TNBCs and inhibiting associated pro‐survival responses to induce deadly metabolic catastrophe. Abstract : Au III prodrugs of anti‐diabetic medicines metformin and phenformin were developed. These compounds effectively decreased triple negative breast tumor burden. The mode of action of novel complexes was linked to energetic crisis and abolishment of pro‐survival responses leading to irreversible cell death.